Ionis Pharmaceuticals, Inc. (IONS) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 159.16M; Formula and calculation Own reported common class count; original count date 2025-04-30. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2025-04-30. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2025-04-30. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2025-04-30. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2025-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 159.16M | Own reported common class count; original count date 2025-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2025-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2025-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2025-04-30. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2025-04-30. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 159.16M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2025-03-31 | 159.16M | (m) | (m) |
| 2024-12-31 | 158.96M | (m) | (m) |
| 2024-09-30 | 157.90M | (m) | (m) |
| 2024-06-30 | 146.21M | (m) | (m) |
| 2024-03-31 | 145.97M | (m) | (m) |
| 2023-12-31 | 145.75M | (m) | (m) |
| 2023-09-30 | 143.47M | (m) | (m) |
| 2023-06-30 | 143.33M | (m) | (m) |
| 2023-03-31 | 143.09M | (m) | (m) |
| 2022-09-30 | 142.05M | (m) | (m) |
| 2022-06-30 | 141.94M | (m) | (m) |
| 2022-03-31 | 141.80M | (m) | (m) |
| 2021-09-30 | 141.21M | (m) | (m) |
| 2021-06-30 | 141.15M | (m) | (m) |
| 2021-03-31 | 140.96M | (m) | (m) |
| 2020-09-30 | 139.82M | (m) | (m) |
| 2020-06-30 | 139.70M | (m) | (m) |
| 2020-03-31 | 139.32M | (m) | (m) |
| 2019-12-31 | 139.22M | (m) | (m) |
| 2019-09-30 | 140.66M | (m) | (m) |
| 2019-06-30 | 140.50M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |